Gujarat Kidney & Super Speciality LtdNSE:GKSL
Current view Q4 2026
Gujarat hospital chain growing by buying hospitals, not organically; own margins slipping. Red flags: restated three years' accounts in court, broke listing rules, and big investors quickly exited.
Latest exchange filings last 5 · 5 after Q4 2026
- 4 Sep ’26Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep ↗
- 3 Sep ’26AGM To Be Held On 28-09-2026 3 Sep ↗
- 3 Sep ’26Revised FY2025-26 annual report filed; 7th AGM on 28 September 2026 with multiple shareholder resolutions. ↗
- 3 Sep ’267th AGM on 28 Sep 2026; shareholders to approve director appointments, remuneration revisions and Rs 500 crore borrowing powers. ↗
- 1 Sep ’267th AGM notice published in newspapers; meeting on 28 September 2026 in physical mode. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +212.7% | +31.5% | — | — |
| Operating profit | ▲ +141.4% | −8.7% | +1085.0% | — |
| EPS | ▲ +178.3% | +73.0% | +65.2% | — |
| PAT | ▲ +259.7% | +30.3% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +212.7%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Good73/100
⚠ Your own view on this company is Negative. Read the note above first — this score reads the figures, and it has not read the concall.
Cheap, and growing fast. Profit per share grew 60% a year, while the price-tag on its earnings actually got smaller. That gap — real growth nobody has paid up for — is exactly what this score looks for.
₹175 → ₹350 needs the P/E at 37× — it is 75× today, and has ranged 63× to 142× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 55× — below anything it traded at in 5 years.
At ₹176 the price-tag on its earnings reaches the 76× it is being projected toward — the point where being cheap against that yardstick is used up.
Growth still unpaid, one leg weaker. Worth the concall read.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a small-cap at ₹1,361 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 60.0% — the weakest of
EPS / Sales / Op-profit from 3-year EPS CAGR, capped at 60%. Latest quarter reads 60%. Price move is a proxy (distance from the 40-week EMA) until ret1y is stored.
How it compares with its rivals Healthcare · 6 of 30 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Gujarat Kidney | ₹184 | 91.4× | ₹1,448 Cr | 14.5% | +7.0% | +124.7% |
| Apollo Hospitals | ₹8,834 | 60.4× | ₹1.27 L Cr | 17.4% | +34.2% | +20.6% |
| Max Healthcare | ₹1,051 | 68.3× | ₹1.02 L Cr | 14.7% | +4.9% | +16.7% |
| Manipal Health | ₹737 | 109.5× | ₹96,989 Cr | 12.1% | −7.9% | +38.1% |
| Fortis Health. | ₹895 | 63.4× | ₹67,603 Cr | 13.4% | +3.4% | +17.5% |
| Aster DM Quality | ₹764 | 184.5× | ₹66,574 Cr | 11.6% | −46.1% | +21.6% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | no — margins have been squeezed | operating margin 52% → 24% over 21 months |
|---|---|---|
| Did the profit turn into cash? | under half — much of the profit is tied up | -14% last year, 52% over three · free cash flow −₹15 cr, positive in 1 of 4 years |
| Is the growth borrowed? | lightly borrowed | ₹29 cr — 0.11× its own equity (was 0.31×) |
| Is it being collected? | customers are taking longer to pay | 172 days to collect, up 34 in a year · cash cycle −84 days |
| Who has been buying? | promoter stake unchanged on record | promoters 71.5% · FIIs 4.9% · DIIs 0.6% |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 14.5% · ROE 11.1% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
Against it
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 172 days.
- Working capital days have increased from 55.7 days to 91.1 days
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.